Raptiva PML Brain Infection Lawsuits: Progressive Multifocal Leukoencephalopathy
The Raptiva lawyers at Saiontz & Kirk, P.A. are reviewing potential lawsuits for users of the psoriasis drug who have developed a rare brain infection, known as progressive multifocal leukoencephalopathy, which has been reported in at least three users.
>>FDA LINK: Raptiva Progressive Multifocal Leukoencephalopathy Advisory
On February 19, 2009, the FDA issued a Public Health Advisiory to notify doctors that three confirmed and one other possible case of progressive multifocal leukoencephalopathy (PML) have been reported among individuals who had been using Raptiva for at least three years. None of these four users were using any other drugs which suppress the immune system and could potentially account for the infection.
Progressive Multifocal Leukoencephalopathy, which is commonly referred to as PML, is a rare brain disease which causes damage to the white matter of the brain at multiple locations and affects the central nervous system. There is no known cure for the disease and in most cases it is fatal. Three of the four identified Raptiva PML cases have already resulted in death.
Symptoms of Progressive Multifocal Leukoencephalopathy from Raptiva could include:
- Weakness
- Paralysis
- Vision Loss
- Impaired Speech
- Cognitive Deterioration
- Death
Information about the possible Raptiva PML brain infection side effects were added to the drug’s label in a “black box” in October 2008. At that time, the label was updated to highlight the risk of progressive multifocal leukoencephalopathy, as well as other opportunistic infections like bacterial sepsis, viral meningitis and invasive fungal disease.
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY LAWYERS
Potential progressive multifocal leukoencephalopathy lawsuits are being reviewed by our lawyers for individuals throughout the United States and there are no fees or expenses unless a recovery is obtained. To have a potential case reviewed by an attorney, request a free consultation and claim evaluation
